$SCNIOct 13, 2026, 7:01 AM ETAI processed
Scinai inks $5.1M CDMO development and clinical manufacturing deal; committed orders rise to $7.6M
AI Summary
Scinai's subsidiary signed a definitive development and clinical manufacturing agreement with a U.S. Nasdaq-listed biopharma for an investigational oncology product, providing approximately $5.1M in committed base service fees expected to translate into revenue as services are performed in 2026–2027. Committed Customer Orders across its facilities rose to ~$7.6M (up ~300% from $1.9M at year-end 2025), and there is an indicative, uncommitted potential for an additional ~$5.85M of clinical manufacturing work in late 2027–H1 2028 subject to scope, pricing, capacity and customer progress.
Positives
- $5.1M in committed base service fees for development and clinical manufacturing
- Committed Customer Orders increased to ~$7.6M, up ~300% from $1.9M at YE2025
- Potential additional uncommitted clinical manufacturing opportunity indicative at ~$5.85M and opens pathway to future commercial manufacturing
Negatives
- $5.1M commitment is subject to performance, contractual terms and termination rights (not guaranteed revenue)
- Additional ~$5.85M value is uncommitted and contingent on final scope, pricing, capacity and regulatory progress
- Revenue recognition and cash timing depend on milestone performance and could be delayed or differ from customer billings